Home
/
KalVista Pharmaceuticals, Inc.
/
Financials
/
Quarterly
KalVista Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that KalVista Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$13.70M
Nov 10, 2025
Q1
2026
Jul 31, 2025
$1.40M
Sep 11, 2025
Q3
2025
Nov 30, 2024
$50.00M
Nov 10, 2025
Q3
2025
Sep 30, 2024
$0
Nov 10, 2025
Q1
2026
Jul 31, 2024
$0
Sep 11, 2025
Q3
2025
Apr 30, 2024
$50.00M
Mar 12, 2025
Q1
2026
Apr 30, 2024
$50.00M
Sep 11, 2025
Q2
2025
Apr 30, 2024
$50.00M
Dec 5, 2024
Q3
2018
Jan 31, 2018
$2.33M
Mar 16, 2018
Q2
2018
Oct 31, 2017
$1.13M
Dec 14, 2017
Q3
2018
Jan 31, 2017
$248.0K
Mar 16, 2018
Q2
2018
Oct 31, 2016
$197.0K
Dec 14, 2017
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$13.69M
Nov 10, 2025
Q1
2026
Jul 31, 2025
$1.43M
Sep 11, 2025
Q3
2021
Jan 31, 2020
$1.58M
Mar 11, 2021
Q2
2021
Oct 31, 2019
$3.92M
Dec 10, 2020
Q1
2021
Jul 31, 2019
$3.37M
Sep 14, 2020
Q3
2020
Jan 31, 2019
$3.89M
Mar 10, 2020
Q2
2020
Oct 31, 2018
$5.59M
Dec 3, 2019
Q1
2020
Jul 31, 2018
$3.72M
Sep 9, 2019
Q3
2019
Jan 31, 2018
$2.33M
Mar 14, 2019
Q2
2019
Oct 31, 2017
$1.13M
Dec 14, 2018
Q1
2019
Jul 31, 2017
$96.0K
Sep 14, 2018
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($49.48M)
Nov 10, 2025
Q1
2026
Jul 31, 2025
($60.10M)
Sep 11, 2025
Q3
2025
Jun 30, 2025
($57.60M)
Nov 10, 2025
Q3
2025
Mar 31, 2025
($51.84M)
Nov 10, 2025
Q3
2025
Jan 31, 2025
($48.51M)
Mar 12, 2025
Q3
2025
Oct 31, 2024
($42.27M)
Mar 12, 2025
Q2
2025
Oct 31, 2024
($42.27M)
Dec 5, 2024
Q3
2025
Sep 30, 2024
($39.08M)
Nov 10, 2025
Q2
2025
Jul 31, 2024
($40.44M)
Dec 5, 2024
Q3
2025
Jul 31, 2024
($40.44M)
Mar 12, 2025
Q1
2026
Jul 31, 2024
($40.44M)
Sep 11, 2025
Q3
2025
Jun 30, 2024
($40.34M)
Nov 10, 2025
Q3
2025
Mar 31, 2024
($43.11M)
Nov 10, 2025
Q3
2025
Jan 31, 2024
($29.03M)
Mar 12, 2025
Q2
2025
Oct 31, 2023
($27.65M)
Dec 5, 2024
Q3
2025
Oct 31, 2023
($27.65M)
Mar 12, 2025
Q3
2025
Jul 31, 2023
($25.32M)
Mar 12, 2025
Q1
2025
Jul 31, 2023
($25.32M)
Sep 5, 2024
Q2
2025
Jul 31, 2023
($25.32M)
Dec 5, 2024
Q3
2024
Jan 31, 2023
($21.30M)
Mar 11, 2024
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($46.05M)
Nov 10, 2025
Q1
2026
Jul 31, 2025
($59.01M)
Sep 11, 2025
Q3
2025
Jan 31, 2025
($42.94M)
Mar 12, 2025
Q2
2025
Oct 31, 2024
($45.81M)
Dec 5, 2024
Q3
2025
Sep 30, 2024
($43.48M)
Nov 10, 2025
Q1
2026
Jul 31, 2024
($44.22M)
Sep 11, 2025
Q3
2025
Jan 31, 2024
($33.15M)
Mar 12, 2025
Q2
2025
Oct 31, 2023
($29.75M)
Dec 5, 2024
Q1
2025
Jul 31, 2023
($29.09M)
Sep 5, 2024
Q3
2024
Jan 31, 2023
($26.95M)
Mar 11, 2024
Q2
2024
Oct 31, 2022
($25.88M)
Dec 7, 2023
Q1
2024
Jul 31, 2022
($26.32M)
Sep 7, 2023
Q3
2023
Jan 31, 2022
($26.68M)
Mar 9, 2023
Q2
2023
Oct 31, 2021
($23.60M)
Dec 8, 2022
Q1
2023
Jul 31, 2021
($19.52M)
Sep 8, 2022
Q3
2022
Jan 31, 2021
($12.66M)
Mar 10, 2022
Q2
2022
Oct 31, 2020
($12.78M)
Dec 9, 2021
Q1
2022
Jul 31, 2020
($14.44M)
Sep 9, 2021
Q3
2021
Jan 31, 2020
($12.72M)
Mar 11, 2021
Q2
2021
Oct 31, 2019
($9.29M)
Dec 10, 2020